Toggle menu

BreathSpec study

Start date:
December 2018
End date:
April 2019
Co-ordinated by:
Julia Grahamslaw
Main trial site:
Liverpool School of Tropical Medicine

A multicentre prospective, observational, longitudinal cohort study in adult patients with suspected upper or lower respiratory infection (URTI/LRTI) to identify a spectrum of biomarkers in exhaled breath to discriminate participants with bacterial RTI from participants without.

Identification of chemical biomarkers in exhaled breath that potentially discriminates participants with bacterial RTI from participants without.

Additional endpoints explored will be variations of the chemical spectrum from all participants using a portable GC-IMS device (Breathspec) stratified by confounding factors, such as (but not limited to) gender, age, antibiotic therapy and smoking status.

 

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Fiona McCurrach

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Alison Williams

Senior Research Nurse

Clare Moceivei

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Sian Dalgleish

Senior Research Nurse

Dr Adam Lloyd

Honorary Research Fellow & Lecturer

Emma Nugent

Research Project Manager

More EMERGE Trials

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA Trial

Evaluating the role of early CT Coronary Angiography

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial